Plasma p-tau217 Discriminates Early-Onset Alzheimer's in Real-World Clinic
This real-world diagnostic study extends plasma p-tau217 validation to early-onset Alzheimer's disease and flags severe renal impairment as a false-positive risk relevant to biomarker interpretation.
📅 Journal publication: Nov 2025(online Sep 11, 2025)·Last updated: Aug 13, 2026
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Chatterjee P, Ivanic S, Southon A, McCarthy C, Patel SK, Christensen M, Darby D, Bush AI, Ayton S, Werden E, Brodtmann A
Citation:Chatterjee P, Ivanic S, Southon A, et al. Real world diagnostic performance of plasma p-tau217 for early-onset Alzheimer's disease in a cognitive disorders tertiary care setting. Journal of Alzheimer's disease : JAD. 2025;108(1):387-396. doi:10.1177/13872877251376694